RT Journal Article
T1 Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease.
A1 Lahuerta, Juan-José
A1 Jiménez-Ubieto, Ana
A1 Paiva, Bruno
A1 Martínez-López, Joaquín
A1 González-Medina, José
A1 López-Anglada, Lucía
A1 Cedena, María-Teresa
A1 Puig, Noemi
A1 Oriol, Albert
A1 Blanchard, María-Jesús
A1 Ríos, Rafael
A1 Martin, Jesús
A1 Martínez, Rafael
A1 Sureda, Anna
A1 Hernández, Miguel Teodoro
A1 de la Rubia, Javier
A1 Krsnik, Isabel
A1 Cabañas, Valentín
A1 Palomera, Luis
A1 Bargay, Joan
A1 Mateos, María-Victoria
A1 Rosiñol, Laura
A1 San Miguel, Jesús F
A1 Blade, Joan
AB Response criteria for multiple myeloma (MM) require monoclonal protein (M-protein)-negative status on both serum immunofixation electrophoresis (sIFE) and urine (uIFE) immunofixation electrophoresis for classification of complete response (CR). However, uIFE is not always performed for sIFE-negative patients. We analyzed M-protein evaluations from 384 MM patients (excluding those with light-chain-only disease) treated in the GEM2012MENOS65 (NCT01916252) trial to determine the uIFE-positive rate in patients who became sIFE-negative posttreatment and evaluate rates of minimal residual disease (MRD)-negative status and progression-free survival (PFS) among patients achieving CR, CR but without uIFE available (uncertain CR; uCR), or very good partial response (VGPR). Among 107 patients with M-protein exclusively in serum at diagnosis who became sIFE-negative posttreatment and who had uIFE available, the uIFE-positive rate was 0%. Among 161 patients with M-protein in both serum and urine at diagnosis who became sIFE-negative posttreatment, 3 (1.8%) were uIFE positive. Among patients achieving CR vs uCR, there were no significant differences in postconsolidation MRD-negative (
YR 2019
FD 2019-04-22
LK http://hdl.handle.net/10668/13863
UL http://hdl.handle.net/10668/13863
LA en
DS RISalud
RD Apr 5, 2025